Cellestis Limited

In a landmark study electronically published today in the American Journal of Respiratory and Critical Care Medicine, a blood test for detecting TB infection, QuantiFERON-TB Gold (QFT), has been shown to be six times more accurate than the conventional tuberculin skin test (TST) at predicting which tuberculosis (TB)-exposed individuals will go on to develop TB disease. This study has important implications for the worldwide effort to eradicate TB, as accurately indentifying TB-infected individuals allows health authorities to treat them before they develop disease, and the greater accuracy of the new test makes this more efficient as well as cheaper and safer.

Cellestis Limited (ASX: CST) is pleased to announce it has been advised by the Korean Food and Drug Administration (KFDA) that QuantiFERON(R)-TB Gold In-Tube has received regulatory approval in the Republic of Korea (South Korea); allowing sale of the test in the Republic of Korea.